c-MET/NF-κB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer. (PubMed, Int Immunopharmacol) - Oct 1, 2026 - "c-MET overexpression promotes immune evasion in NSCLC, potentially through NF-κB-mediated upregulation of PD-L1 and CCL22. Combined MET inhibition and immune checkpoint blockade represents a promising strategy for this patient subset."
IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CCL2 • CCL22 • CD8 • MET • PD-L1
|
|
Chunyang Su; Hao Chen; Jinyang Zheng; Lijin Chen; Liping Zhang; Rencai Fan; Xiaofeng Li; Xiaoyan Lin; Xihu Yao
|